<DOC>
	<DOCNO>NCT01518881</DOCNO>
	<brief_summary>This phase 1 , single-center , placebo-controlled , single-blind , first-in-human , single-ascending dose study additional multiple-ascending dose cohort healthy male female volunteer .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic First Human ( FIH ) Study Intravenous ( IV ) TKM-100201 Infusion</brief_title>
	<detailed_description>A maximum 56 healthy adult ( male female ) subject participate study , two stage . In Stage 1 , Single-Ascending Dose ( SAD ) phase study six cohort 4 subject ( 3 receive TKM-100201 1 receive saline placebo ) cohort . Additional cohort may enrol maximum tolerate dose ( MTD ) establish initial six cohort . In Stage 2 , Multiple-Ascending Dose ( MAD ) portion study three cohort four subject ( 3 receive TKM-100201 1 receive saline placebo ) cohort . Additional cohort may enrol maximum tolerate dose ( MTD ) establish initial three cohort .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>1 . Informed nature study agree able read , review sign informed consent document screening . The informed consent document write English , therefore volunteer must ability read communicate English . 2 . Able comply protocolspecified visit schedule requirement . 3 . Completed screen process within 14 day prior dose . 4 . Healthy male female volunteer 18 50 year age , inclusive , time dose . 5 . Body mass index ( BMI ) 22 kg/m2 35 kg/m2 , inclusive , weigh least 110 lb . 6 . Judged Investigator good health document medical history , physical examination ( include may limited evaluation cardiovascular , gastrointestinal , respiratory central nervous system ) , vital sign assessment , 12lead ECG , clinical laboratory assessment , general observation . Any abnormality deviation outside normal range clinical testing ( laboratory test , ECG , vital sign ) repeat discretion Investigator ( ) judge clinically significant study participation . 7 . Adequate hepatic , renal , hematologic clot function define total bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , serum creatinine , Ddimer International normalize ratio ( INR ) within normal range determine Investigator ( ) Sponsor Medical Monitor . 8 . Female volunteer must one following : naturally postmenopausal ( menses ) &gt; 2 year document FSH level &gt; 40 mIU/mL ; document history ovarian failure ; surgically postmenopausal ( bilateral oophorectomy hysterectomy ) . Female volunteer surgically postmenopausal must provide documentation bilateral oophorectomy hysterectomy prior Day 1 dose eligible participation study ; Women childbearing potential ( FSH â‰¤40 mIU/mL ) must negative serum hCG screening , negative urine pregnancy test prior first study treatment , must agree utilize highly effective contraception method ( two separate form contraception , one must effective barrier method , nonheterosexually active , vasectomized partner ) screen throughout duration study treatment 1 month last administration investigational product . 9 . Male volunteer sexually active must willing use effective barrier contraception ( e.g. , condom spermicide ) heterosexual intercourse screen throughout duration study treatment 1 month last dose investigational product . 1 . Evidence history clinically significant hematologic , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic allergic disease screen medication comorbidity , dialogue Investigator Medical Monitor would preclude subject participation clinical trial . 2 . Reports uncontrolled psychiatric disorder neurologic disease seizure disorder control medication . 3 . Subject history exist clinically significant cardiovascular disease ( example , uncontrolled hypertension , unstable angina , congestive heart failure serious cardiac arrhythmia ) . In addition New York Heart Association Functional Classification Class II great exclude ( see Appendix ) . 4 . Reports history coronary heart disease ( CHD ) , CHDequivalent disease CHD risk &gt; 20 % designate National Cholesterol Education Program Adult Treatment Panel III . 5 . Current diagnosis know history liver disease ( e.g . acute chronic hepatitis liver cirrhosis ) . 6 . Presence clinically significant result laboratory test , vital sign assessment ECGs judge Investigator ( ) . 7 . Reports receive antiviral drug , investigational drug , biologics , device within 28 day prior study treatment plan use course study . 8 . Reports receive naturopathic medication , herbal supplement , lipid lower therapy within 28 day prior study treatment plan use course study . 9 . Recent treatment alternative therapy , view Investigator ( ) Medical Monitor , could potentially confound clinical laboratory assessment . 10 . Demonstrates mark baseline prolongation QT/QTc interval ( e.g . repeat demonstration QTc interval &gt; 450 m ) 11 . Reports concomitant use medication prolongs QT/QTc interval . 12 . Reports history additional risk factor torsades de pointes ( e.g . heart failure , hypokalemia , family history Long QT Syndrome ) . 13 . When confirm upon additional testing , demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . 14 . Reports infection require antibiotic therapy within 30 day screen ( determine Investigator [ ] ) . 15 . Reports history Ebola virus exposure . 16 . Reports occupational health risk exposure Ebola virus know higher general population . 17 . Reports know suspected hypersensitivity previous severe reaction constituent investigational product include oligonucleotide lipidbased product , liposomal drug product , phospholipidbased product ( parenteral nutrition , Intralipid ) . 18 . Reports history clinically significant allergy include food drug allergy . 19 . Demonstrates positive drug alcohol screen . 20 . Reports history drug alcohol addiction abuse within past 1 year . 21 . Subject unwilling limit alcohol consumption study ( male : 2 drinks/day [ 30 g ] , &lt; 12 drinks/week [ 120 g ] female : 2 drinks/day [ 20 g ] , &lt; 12drinks/week [ 120 g ] ) . 22 . Reports donate blood within 28 day prior dose . All volunteer advise donate blood four week complete study . 23. port donate plasma ( eg , plasmapheresis ) within 14 day prior dose . All volunteer advise donate plasma four week complete study . 24 . Demonstrates , opinion study staff , vein unsuitable repeated venipuncture IV infusion ( eg , vein difficult locate , access , puncture ; vein tendency rupture puncture ) . 25 . Reports capable become pregnant , breastfeeding , lactate . 26 . Demonstrates positive pregnancy screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>